三氧化二锑_MSDS_用途_密度_三氧化二锑CAS号【1309-64-4】

【用途一】
用作白色颜料、白色玻璃、搪瓷、药物、胶合水泥、填充剂、媒染剂及防火涂料等
【用途二】
作为阻燃剂广泛用于塑料、橡胶、纺织、化纤、颜料、油漆、电子等行业，也用作化工行业的催化剂和生产原料
【用途三】
用作高纯试剂、媒染剂及防光剂，也用于颜料及酒石酸锑钾的制备
【用途四】
用作各种树脂、合成橡胶、帆布、纸张、涂料等的阻燃剂，石油化工、合成纤维的催化剂。用于制造媒染剂、乳白剂，是合成锑盐的原料。搪瓷工业用作添加剂，以增加珐琅的不透明性和表面光泽。玻璃工业用作代替亚砷酸的脱色剂。医药、冶金、军工等。
【用途五】
优良的无机白色颜料，主要用于油漆的着色。用于各种树脂、合成橡胶、帆布、纸张、涂料等的阻燃剂，石油化工、合成纤维的催化剂。用于制造媒染剂、乳白剂，是合成锑盐的原料。搪瓷工业用作增加珐琅的不透明性和表面光泽。玻璃工业用作代替亚砷酸的脱色剂。
【用途六】
三氧化二锑是一种良好的遮盖剂，用作白色油漆颜料。用作各种树脂、合成橡胶帆布、纸张、涂料等的阻燃剂，石油化工、合成纤维的催化剂。用于制造媒染剂、乳白剂，用于制白色玻璃、搪瓷、吐酒石、药物、胶合水泥，也是合成锑盐的原料，搪瓷工业添加剂，以增加珐琅的不透明性和表面光泽。玻璃工业用作代替亚砷酸的脱色剂等。制备酒石酸锑钾

点击显示

[ 密度 ]:
5.20

[ 沸点 ]:
1550 °C(lit.)

[ 熔点 ]:
655 °C(lit.)

[ 分子式 ]:
O₃Sb₂

[ 分子量 ]:
291.518

[ 闪点 ]:
1550°C subl.

[ 精确质量 ]:
289.792389

[ PSA ]:
43.37000

[ 外观性状 ]:
白色粉末

[ 储存条件 ]:
库房通风低温干燥,与食品原料,BRF3和氯化了的橡胶分开存放

[ 稳定性 ]:
Stable.

[ 水溶解性 ]:
Slightly soluble.

详细MSDS(安全技术说明书)

CHEMICAL IDENTIFICATION

RTECS NUMBER :: CC5650000

CHEMICAL NAME :: Antimony oxide

CAS REGISTRY NUMBER :: 1309-64-4

LAST UPDATED :: 199712

DATA ITEMS CITED :: 63

MOLECULAR FORMULA :: O3-Sb2

MOLECULAR WEIGHT :: 291.50

WISWESSER LINE NOTATION :: .SB2.O3

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: Standard Draize test

ROUTE OF EXPOSURE :: Administration into the eye

SPECIES OBSERVED :: Rodent - rabbit

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: >34600 mg/kg

TOXIC EFFECTS :: Behavioral - somnolence (general depressed activity) Skin and Appendages - hair

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 3250 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 7904 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 172 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Mammal - dog

DOSE/DURATION :: 3 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Administration onto the skin

SPECIES OBSERVED :: Rodent - rabbit

DOSE/DURATION :: 2 gm/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - rabbit

DOSE/DURATION :: 2500 ug/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD - Lethal dose

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Mammal - species unspecified

DOSE/DURATION :: >120 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: TCLo - Lowest published toxic concentration

ROUTE OF EXPOSURE :: Inhalation

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 72 ug/m3/24H/17W-C

TOXIC EFFECTS :: Blood - pigmented or nucleated red blood cells Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - true cholinesterase Biochemical - Metabolism (Intermediary) - lipids including transport

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 25688 mg/kg/13W-I

TOXIC EFFECTS :: Cardiac - other changes

TYPE OF TEST :: TCLo - Lowest published toxic concentration

ROUTE OF EXPOSURE :: Inhalation

SPECIES OBSERVED :: Rodent - guinea pig

DOSE/DURATION :: 45 mg/m3/10W-I

TOXIC EFFECTS :: Lungs, Thorax, or Respiration - fibrosis, focal (pneumoconiosis) Liver - fatty liver degeneration Related to Chronic Data - death

TYPE OF TEST :: TCLo - Lowest published toxic concentration

ROUTE OF EXPOSURE :: Inhalation

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 4200 ug/m3/52W-I

TOXIC EFFECTS :: Tumorigenic - Carcinogenic by RTECS criteria Lungs, Thorax, or Respiration - tumors Liver - tumors

TYPE OF TEST :: TC - Toxic concentration (other than lowest)

ROUTE OF EXPOSURE :: Inhalation

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 4 mg/m3/1Y-I

TOXIC EFFECTS :: Tumorigenic - equivocal tumorigenic agent by RTECS criteria Lungs, Thorax, or Respiration - tumors Liver - tumors

TYPE OF TEST :: TC - Toxic concentration (other than lowest)

ROUTE OF EXPOSURE :: Inhalation

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 1600 ug/m3/52W-I

TOXIC EFFECTS :: Tumorigenic - neoplastic by RTECS criteria Liver - tumors Skin and Appendages - tumors

TYPE OF TEST :: TC - Toxic concentration (other than lowest)

ROUTE OF EXPOSURE :: Inhalation

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 50 mg/m3/7H/52W-I

TOXIC EFFECTS :: Tumorigenic - Carcinogenic by RTECS criteria Lungs, Thorax, or Respiration - tumors

TYPE OF TEST :: TCLo - Lowest published toxic concentration

ROUTE OF EXPOSURE :: Inhalation

DOSE :: 270 ug/m3

SEX/DURATION :: female 1-21 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetal death

TYPE OF TEST :: TCLo - Lowest published toxic concentration

ROUTE OF EXPOSURE :: Inhalation

DOSE :: 82 ug/m3

SEX/DURATION :: female 1-21 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - pre-implantation mortality (e.g. reduction in number of implants per female; total number of implants per corpora lutea) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)

TYPE OF TEST :: TCLo - Lowest published toxic concentration

ROUTE OF EXPOSURE :: Inhalation

DOSE :: 270 ug/m3/24H

SEX/DURATION :: female 1-21 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - pre-implantation mortality (e.g. reduction in number of implants per female; total number of implants per corpora lutea) Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetal death

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intratesticular

DOSE :: 23320 ug/kg

SEX/DURATION :: male 1 day(s) pre-mating

TOXIC EFFECTS :: Reproductive - Paternal Effects - spermatogenesis (incl. genetic material, sperm morphology, motility, and count) Reproductive - Paternal Effects - testes, epididymis, sperm duct

MUTATION DATA

TYPE OF TEST :: Sister chromatid exchange

TEST SYSTEM :: Rodent - hamster Lung

REFERENCE :: MUREAV Mutation Research. (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1- 1964- Volume(issue)/page/year: 264,163,1991 *** REVIEWS *** ACGIH TLV-TWA 0.5 mg(Sb)/m3 (Sb2O3 handling/use) DTLVS* The Threshold Limit Values (TLVs) and Biological Exposure Indices (BEIs) booklet issues by American Conference of Governmental Industrial Hygienists (ACGIH), Cincinnati, OH, 1996 Volume(issue)/page/year: TLV/BEI,1997 ACGIH TLV-Suspected human carcinogen DTLVS* The Threshold Limit Values (TLVs) and Biological Exposure Indices (BEIs) booklet issues by American Conference of Governmental Industrial Hygienists (ACGIH), Cincinnati, OH, 1996 Volume(issue)/page/year: TLV/BEI,1997 IARC Cancer Review:Animal Sufficient Evidence IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972- Volume(issue)/page/year: 47,291,1989 IARC Cancer Review:Human Inadequate Evidence IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972- Volume(issue)/page/year: 47,291,1989 IARC Cancer Review:Group 2B IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972- Volume(issue)/page/year: 47,291,1989 *** U.S. STANDARDS AND REGULATIONS *** OSHA PEL (Gen Indu):8H TWA 0.5 mg(Sb)/m3 CFRGBR Code of Federal Regulations. (U.S. Government Printing Office, Supt. of Documents, Washington, DC 20402) Volume(issue)/page/year: 29,1910.1000,1994 OSHA PEL (Construc):8H TWA 0.5 mg(Sb)/m3 CFRGBR Code of Federal Regulations. (U.S. Government Printing Office, Supt. of Documents, Washington, DC 20402) Volume(issue)/page/year: 29,1926.55,1994 OSHA PEL (Shipyard):8H TWA 0.5 mg(Sb)/m3 CFRGBR Code of Federal Regulations. (U.S. Government Printing Office, Supt. of Documents, Washington, DC 20402) Volume(issue)/page/year: 29,1915.1000,1993 OSHA PEL (Fed Cont):8H TWA 0.5 mg(Sb)/m3 CFRGBR Code of Federal Regulations. (U.S. Government Printing Office, Supt. of Documents, Washington, DC 20402) Volume(issue)/page/year: 41,50-204.50,1994 *** OCCUPATIONAL EXPOSURE LIMITS *** OEL-ARAB Republic of Egypt:TWA 0.5 mg(Sb)/m3 JAN 1993 OEL-AUSTRALIA:STEL 0.5 ppm JAN 1993 OEL-AUSTRALIA:TWA 0.5 mg(Sb)/m3 JAN 1993 OEL-AUSTRIA:TWA 0.5 mg(Sb)/m3 JAN 1993 OEL-BELGIUM:STEL 0.5 ppm JAN 1993 OEL-BELGIUM:TWA 0.5 mg(Sb)/m3 JAN 1993 OEL-DENMARK:TWA 0.5 mg(Sb)/m3 JAN 1993 OEL-FINLAND:.TWA (0.5 mg(Sb)/m3) JAN 1993 OEL-FRANCE:TWA 0.5 mg(Sb)/m3 JAN 1993 OEL-GERMANY:TWA 0.5 mg(Sb)/m3 (total dust) JAN 1993 OEL-GERMANY;Carcinogen JAN 1993 OEL-HUNGARY:STEL 0.5 mg(Sb)/m3 JAN 1993 OEL-THE NETHERLANDS:TWA 0.5 mg(Sb)/m3 JAN 1993 OEL-THE PHILIPPINES:TWA 0.5 mg(Sb)/m3 JAN 1993 OEL-POLAND:TWA 0.5 mg(Sb)/m3 JAN 1993 OEL-RUSSIA:STEL 1 mg/m3 JAN 1993 OEL-RUSSIA:TWA 0.2 mg(Sb)/m3;STEL 0.5 mg(Sb)/m3 JAN 1993 OEL-SWEDEN:TWA 0.5 mg(Sb)/m3 JAN 1993 OEL-SWITZERLAND:TWA 0.1 mg/m3;Carcinogen JAN 1993 OEL-SWITZERLAND:TWA 0.5 mg(Sb)/m3 JAN 1993 OEL-TURKEY:TWA 0.5 mg(Sb)/m3 JAN 1993 OEL-UNITED KINGDOM:TWA 0.5 mg(Sb)/m3 JAN 1993 OEL IN BULGARIA, COLOMBIA, JORDAN, KOREA check ACGIH TLV OEL IN NEW ZEALAND, SINGAPORE, VIETNAM check ACGIH TLV *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH RECOMMENDED EXPOSURE LEVEL (REL) : NIOSH REL TO ANTIMONY-air:10H TWA 0.5 mg(Sb)/m3 REFERENCE : NIOSH* National Institute for Occupational Safety and Health, U.S. Dept. of Health, Education, and Welfare, Reports and Memoranda. Volume(issue)/page/year: DHHS #92-100,1992 NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOHS - National Occupational Hazard Survey (1974) NOHS Hazard Code - M2263 No. of Facilities: 1540 (estimated) No. of Industries: 31 No. of Occupations: 53 No. of Employees: 28957 (estimated) NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - M2263 No. of Facilities: 7476 (estimated) No. of Industries: 72 No. of Occupations: 76 No. of Employees: 209773 (estimated) No. of Female Employees: 56911 (estimated)

点击显示

[ 符号 ]:

GHS08

[ 信号词 ]:
Warning

[ 危害声明 ]:
H351

[ 警示性声明 ]:
P281

[ 个人防护装备 ]:
Eyeshields;full-face particle respirator type N100 (US);Gloves;respirator cartridge type N100 (US);type P1 (EN143) respirator filter;type P3 (EN 143) respirator cartridges

[ 危害码 (欧洲) ]:
Xn:Harmful;

[ 风险声明 (欧洲) ]:
R40:;

[ 安全声明 (欧洲) ]:
S22-S36/37

[ 危险品运输编码 ]:
1549

[ WGK德国 ]:
2

[ RTECS号 ]:
CC5650000

[ 包装等级 ]:
III

[ 危险类别 ]:
6.1

[ 海关编码 ]:
2825800000

分为干法和湿法。干法是由辉锑矿或金属锑经焙烧氧化制得产品的方法。湿法是辉锑矿或金属锑采用液相法与酸反应制得产品的方法。
1. 干法辉锑矿(Sb2S3)于1000℃在焦炭存在下煅烧。将氧化生成的三氧化二锑蒸气收集起来，经冷凝后，用纯碱做助熔剂，与焦炭经加热还原生成金属锑。所得金属锑再在空气中氧化即得三氧化二锑。其反应式： 2. 湿法锑盐氨解法将金属锑与氯气反应生成三氯化锑，经蒸馏、水解、氨解、洗涤、离心分离、干燥，制得三氧化二锑成品。以辉锑矿为原料盐酸法辉锑矿与盐酸作用，在硝酸存在下发生反应，经水解、沉淀、烘干即得成品。

3.由金属锑在空气中熔化或燃烧制得。
4. 将相对密度为1.19的盐酸与水等体积混合，然后在搅拌下将三氯化锑溶于其中，再慢慢加到煮沸的
碳酸钠溶液中，继续煮沸：当不再有 CO ₂ 气体逸出后，停止加热，分离出沉淀，用热水洗涤至洗液中不含Cl ^- 离子，之后于150℃烘干，即可。
5. 将7kg高纯三氯化锑加热溶解后，在不断搅拌下，慢慢加到90L沸腾的电导水中，以生成白色氯氧化锑和三氧化二锑的混合沉淀。再加入28%的高纯氨水至溶液pH=8-9，静置，待沉淀完全后，过滤，沉淀物再用50L热电导水加热煮沸，用高纯氨水调pH=8-9，反复5次，至溶液中不含Cl ^-离子，过滤后于120℃烘16h，即得高纯三氧化二锑（99.99％）。 4. 辉锑矿法　以辉锑矿为原料制备三氧化二锑，反应式如下:

将含锑大于60%的辉锑精矿与焦炭充分混合，放入加热炉中于800～1000℃氧化焙烧，严格控制氧化焙烧温度和加热炉氧化气氛，以保证辉锑矿完全氧化成粗氧化锑。挥发的三氧化二锑与炉气一同进入冷却系统，迅速冷却到小于150℃，在布袋中收集得粗三氧化二锑。然后放入还原炉中，在焦炭存在下，以碱作助熔剂加热还原成金属锑。再将金属锑放入加热炉中，控制温度在1000℃左右，通空气氧化锑成三氧化二锑蒸气，经冷凝系统冷却，在布袋中收集制得产品。

以辉锑矿为原料，也可采用下法制备三氧化二锑，反应式如下：

将含锑大于60%的辉锑矿用三氯化铁和盐酸溶液浸取，三氯化锑过量10%～30%，保持浸出液一定酸性，以防止三氯化锑水解。过滤后的浸出液用锑粉在常温和搅拌情况下还原，除去Ｆｅ３＋、Ｓｂ５＋的干扰，再过滤后的滤液加水进行水解，在常温下水解完成后过滤，滤饼用氨水进行中和，控制ｐＨ＝7～8，当ｐＨ值稳定在8时，完成中和反应，经过滤、滤饼干燥得产品。

氨解法　以粗三氧化二锑或锑为原料制备三氧化二锑，反应式如下：

将粗三氧化二锑加入反应器中，通入30%的盐酸，在搅拌下溶解成三氧化二锑，过滤。滤液在水解槽中通入水水解生成氧氯化锑，水解完成后用氨水进行中和，控制ｐＨ＝8左右，中和完成后过滤、用水洗涤，滤饼经干燥制得产品。

低频等离子法　将等离子体发生器的电极油水分离，送料系统和主反应器内壁结构进行多处和改进创新，生产出0.07μm超细三氧化二锑产品白度高，活性好。

点击显示

[ 海关编码 ]: 2825800000

Dermatitis in workers exposed to antimony in a melting process.

J. Occup. Med. 35(4) , 392-5, (1993)

An employee at a brazing rod manufacturing plant developed a generalized eruption of follicular papules and pustules. His job tasks included breaking up antimony ingots and melting the pieces in a cru...

Characterization of pyramidal inversion boundaries in Sb2O3-doped ZnO by using electron back-scattered diffraction (EBSD).

Acta Crystallogr. A 63(Pt 3) , 229-33, (2007)

The composition planes of the inversion boundary induced by the addition of Sb2O3 to ZnO ceramics were analyzed crystallographically by the application of electron back-scattered diffraction (EBSD) an...

Biovolatilization of antimony and sudden infant death syndrome (SIDS).

Hum. Exp. Toxicol. 17(4) , 231-8, (1998)

1. The aerobic filamentous fungus S. brevicaulis IMI 17297 methylated antimony from Sb2O3 substrate, with the formation of gaseous trimethylantimony (TMA). No evidence was found for the generation of ...

更多文献